Logo image of 1CVAC.MI

CUREVAC NV (1CVAC.MI) Stock Fundamental Analysis

BIT:1CVAC - Euronext Milan - NL0015436031 - Common Stock - Currency: EUR

4.798  +2.3 (+91.92%)

Fundamental Rating

4

Overall 1CVAC gets a fundamental rating of 4 out of 10. We evaluated 1CVAC against 73 industry peers in the Biotechnology industry. The financial health of 1CVAC is average, but there are quite some concerns on its profitability. 1CVAC is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 1CVAC was profitable.
1CVAC had a negative operating cash flow in the past year.
1CVAC had negative earnings in each of the past 5 years.
1CVAC had negative operating cash flow in 4 of the past 5 years.
1CVAC.MI Yearly Net Income VS EBIT VS OCF VS FCF1CVAC.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M -600M -800M

1.2 Ratios

1CVAC has a worse Return On Assets (-50.00%) than 61.64% of its industry peers.
With a Return On Equity value of -73.95%, 1CVAC perfoms like the industry average, outperforming 46.58% of the companies in the same industry.
Industry RankSector Rank
ROA -50%
ROE -73.95%
ROIC N/A
ROA(3y)-32.5%
ROA(5y)-36.5%
ROE(3y)-52.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1CVAC.MI Yearly ROA, ROE, ROIC1CVAC.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200

1.3 Margins

1CVAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1CVAC.MI Yearly Profit, Operating, Gross Margins1CVAC.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

1CVAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1CVAC has been increased compared to 1 year ago.
The number of shares outstanding for 1CVAC has been increased compared to 5 years ago.
Compared to 1 year ago, 1CVAC has a worse debt to assets ratio.
1CVAC.MI Yearly Shares Outstanding1CVAC.MI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
1CVAC.MI Yearly Total Debt VS Total Assets1CVAC.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 3.17 indicates that 1CVAC is not in any danger for bankruptcy at the moment.
The Altman-Z score of 1CVAC (3.17) is better than 78.08% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1CVAC is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.09, 1CVAC is doing good in the industry, outperforming 65.75% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.17
ROIC/WACCN/A
WACC7.05%
1CVAC.MI Yearly LT Debt VS Equity VS FCF1CVAC.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 500M -500M

2.3 Liquidity

1CVAC has a Current Ratio of 2.29. This indicates that 1CVAC is financially healthy and has no problem in meeting its short term obligations.
1CVAC has a Current ratio of 2.29. This is comparable to the rest of the industry: 1CVAC outperforms 54.79% of its industry peers.
1CVAC has a Quick Ratio of 2.28. This indicates that 1CVAC is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.28, 1CVAC is doing good in the industry, outperforming 61.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.28
1CVAC.MI Yearly Current Assets VS Current Liabilites1CVAC.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 138.45% over the past year.
The Revenue for 1CVAC has decreased by -20.24% in the past year. This is quite bad
The Revenue has been growing by 33.04% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)138.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%806.58%
Revenue 1Y (TTM)-20.24%
Revenue growth 3Y3.21%
Revenue growth 5Y33.04%
Sales Q2Q%3002.48%

3.2 Future

The Earnings Per Share is expected to grow by 9.02% on average over the next years. This is quite good.
The Revenue is expected to grow by 17.56% on average over the next years. This is quite good.
EPS Next Y76.81%
EPS Next 2Y28.17%
EPS Next 3Y22.51%
EPS Next 5Y9.02%
Revenue Next Year112.91%
Revenue Next 2Y3.11%
Revenue Next 3Y32.25%
Revenue Next 5Y17.56%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1CVAC.MI Yearly Revenue VS Estimates1CVAC.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
1CVAC.MI Yearly EPS VS Estimates1CVAC.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

1CVAC is valuated reasonably with a Price/Earnings ratio of 9.05.
Based on the Price/Earnings ratio, 1CVAC is valued cheaply inside the industry as 93.15% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of 1CVAC to the average of the S&P500 Index (26.34), we can say 1CVAC is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for 1CVAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 9.05
Fwd PE N/A
1CVAC.MI Price Earnings VS Forward Price Earnings1CVAC.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1CVAC.MI Per share data1CVAC.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

1CVAC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1CVAC's earnings are expected to grow with 22.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y28.17%
EPS Next 3Y22.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1CVAC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUREVAC NV

BIT:1CVAC (6/13/2025, 7:00:00 PM)

4.798

+2.3 (+91.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.08B
Analysts77.33
Price Target7.53 (56.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.84%
Min EPS beat(2)-33.3%
Max EPS beat(2)-18.39%
EPS beat(4)1
Avg EPS beat(4)-38.24%
Min EPS beat(4)-106.68%
Max EPS beat(4)5.4%
EPS beat(8)3
Avg EPS beat(8)-29.57%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)80.49%
Min Revenue beat(2)0.83%
Max Revenue beat(2)160.16%
Revenue beat(4)2
Avg Revenue beat(4)30.79%
Min Revenue beat(4)-34.43%
Max Revenue beat(4)160.16%
Revenue beat(8)2
Avg Revenue beat(8)-5.94%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.6%
PT rev (3m)-6.6%
EPS NQ rev (1m)357.64%
EPS NQ rev (3m)357.64%
EPS NY rev (1m)71.62%
EPS NY rev (3m)71.62%
Revenue NQ rev (1m)594.85%
Revenue NQ rev (3m)594.85%
Revenue NY rev (1m)134.55%
Revenue NY rev (3m)134.55%
Valuation
Industry RankSector Rank
PE 9.05
Fwd PE N/A
P/S 16.34
P/FCF N/A
P/OCF N/A
P/B 2.86
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)0.53
EY11.05%
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0.29
BVpS1.68
TBVpS1.56
PEG (NY)0.12
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50%
ROE -73.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.5%
ROA(5y)-36.5%
ROE(3y)-52.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 184.54%
Cap/Sales 61.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 2.28
Altman-Z 3.17
F-Score2
WACC7.05%
ROIC/WACCN/A
Cap/Depr(3y)481.31%
Cap/Depr(5y)411.27%
Cap/Sales(3y)121.71%
Cap/Sales(5y)106.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)138.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%806.58%
EPS Next Y76.81%
EPS Next 2Y28.17%
EPS Next 3Y22.51%
EPS Next 5Y9.02%
Revenue 1Y (TTM)-20.24%
Revenue growth 3Y3.21%
Revenue growth 5Y33.04%
Sales Q2Q%3002.48%
Revenue Next Year112.91%
Revenue Next 2Y3.11%
Revenue Next 3Y32.25%
Revenue Next 5Y17.56%
EBIT growth 1Y5.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.68%
EBIT Next 3Y23.77%
EBIT Next 5Y32.39%
FCF growth 1Y14.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.4%
OCF growth 3YN/A
OCF growth 5YN/A